CXCR4 and breast cancer: Since CXCR4 signaling mechanistically drives ER-positive breast cancers to metastatic and endocrine therapy-resistant phenotypes, PET imaging with [68Ga]Pentixafor might play a role in providing spatiotemporal information over the course of endocrine therapy [66].